• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Hartmann KE, McPheeters ML, Biller DH, et al. Treatment of Overactive Bladder in Women. Rockville (MD): Agency for Healthcare Research and Quality (US); 2009 Aug. (Evidence Reports/Technology Assessments, No. 187.)

References and Included Studies

1.
U. S. Census Bureau. May 1, 2008. Table 2. Annual Estimates of the Population by Sex and Selected Age Groups for the United States: April 1, 2000 to July 1, 2007 (NC-EST2007-02).
2.
Lawrence JM, Lukacz ES, Nager CW, et al. Prevalence and co-occurrence of pelvic floor disorders in community-dwelling women. Obstet Gynecol. 2008 Mar;111(3):678–85. [PubMed: 18310371]
3.
Lukacz ES, Lawrence JM, Contreras R, et al. Parity, mode of delivery, and pelvic floor disorders. Obstet Gynecol. 2006 Jun;107(6):1253–60. [PubMed: 16738149]
4.
Wagner TH, Hu TW, Bentkover J, et al. Health-related consequences of overactive bladder. Am J Manag Care. 2002 Dec;8(19 Suppl):S598–607. [PubMed: 12516954]
5.
Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5(1):13. [PMC free article: PMC1097734] [PubMed: 15840177]
6.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 Sep;7(3):177–88. [PubMed: 3802833]
7.
Sismondo S. How pharmaceutical industry funding affects trial outcomes: causal structures and responses. Soc Sci Med. 2008 May;66(9):1909–14. [PubMed: 18299169]
8.
Sismondo S. Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemp Clin Trials. 2008 Mar;29(2):109–13. [PubMed: 17919992]
9.
Lexchin J, Bero LA, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003 May 31;326(7400):1167–70. [PMC free article: PMC156458] [PubMed: 12775614]
10.
Fenner DE, Trowbridge ER, Patel DL, et al. Establishing the prevalence of incontinence study: racial differences in women's patterns of urinary incontinence. J Urol. 2008 Apr;179(4):1455–60. [PMC free article: PMC2879624] [PubMed: 18295278]
11.
Dooley Y, Kenton K, Cao G, et al. Urinary incontinence prevalence: results from the National Health and Nutrition Examination Survey. J Urol. 2008 Feb;179(2):656–61. [PubMed: 18082211]
12.
Herschorn S, Gajewski J, Schulz J, et al. A population-based study of urinary symptoms and incontinence: the Canadian Urinary Bladder Survey. BJU Int. 2008 Jan;101(1):52–8. [PubMed: 17908260]
13.
Lawrence JM, Lukacz ES, Liu IL, et al. Pelvic floor disorders, diabetes, and obesity in women: findings from the Kaiser Permanente Continence Associated Risk Epidemiology Study. Diabetes Care. 2007 Oct;30(10):2536–41. [PubMed: 17620443]
14.
Choo MS, Ku JH, Lee JB, et al. Cross-cultural differences for adapting overactive bladder symptoms: results of an epidemiologic survey in Korea. World J Urol. 2007 Oct;25(5):505–11. [PubMed: 17569056]
15.
Townsend MK, Danforth KN, Lifford KL, et al. Incidence and remission of urinary incontinence in middle-aged women. Am J Obstet Gynecol. 2007 Aug;197(2):167 e1–5. [PMC free article: PMC3025861] [PubMed: 17689637]
16.
Link CL, Lutfey KE, Steers WD, et al. Is abuse causally related to urologic symptoms? Results from the Boston Area Community Health (BACH) Survey. Eur Urol. 2007 Aug;52(2):397–406. [PMC free article: PMC2139977] [PubMed: 17383083]
17.
Waetjen LE, Liao S, Johnson WO, et al. Factors associated with prevalent and incident urinary incontinence in a cohort of midlife women: a longitudinal analysis of data: study of women's health across the nation. Am J Epidemiol. 2007 Feb 1;165(3):309–18. [PubMed: 17132698]
18.
Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006 Dec;50(6):1306–14. discussion 1314–5. [PubMed: 17049716]
19.
Huang AJ, Thom DH, Kanaya AM, et al. Urinary incontinence and pelvic floor dysfunction in Asian-American women. Am J Obstet Gynecol. 2006 Nov;195(5):1331–7. [PMC free article: PMC1630451] [PubMed: 16643821]
20.
Hsieh CH, Chen HY, Hsu CS, et al. Prevalence of urinary frequency in Taiwanese women aged 20–59 years. Taiwan J Obstet Gynecol. 2006 Sep;45(3):244–6. [PubMed: 17175472]
21.
Homma Y, Yamaguchi O, Hayashi K. Epidemiologic survey of lower urinary tract symptoms in Japan. Urology. 2006 Sep;68(3):560–4. [PubMed: 16979726]
22.
Odeyemi IA, Dakin HA, O'Donnell RA, et al. Epidemiology, prescribing patterns and resource use associated with overactive bladder in UK primary care. Int J Clin Pract. 2006 Aug;60(8):949–58. [PubMed: 16893437]
23.
Teloken C, Caraver F, Weber FA, et al. Overactive bladder: prevalence and implications in Brazil. Eur Urol. 2006 Jun;49(6):1087–92. [PubMed: 16497431]
24.
Kim SH, Boye M, Bhattacharyya SK, et al. Medical visits among adults with symptoms commonly associated with an overactive bladder. BJU Int. 2006 Mar;97(3):551–4. [PubMed: 16469024]
25.
Fitzgerald MP, Thom DH, Wassel-Fyr C, et al. Childhood urinary symptoms predict adult overactive bladder symptoms. J Urol. 2006 Mar;175(3 Pt 1):989–93. [PMC free article: PMC1820589] [PubMed: 16469599]
26.
McGrother CW, Donaldson MM, Hayward T, et al. Urinary storage symptoms and comorbidities: a prospective population cohort study in middle-aged and older women. Age Ageing. 2006 Jan;35(1):16–24. [PubMed: 16234314]
27.
Thom DH, van den Eeden SK, Ragins AI, et al. Differences in prevalence of urinary incontinence by race/ethnicity. J Urol. 2006 Jan;175(1):259–64. [PMC free article: PMC1557354] [PubMed: 16406923]
28.
Donaldson MM, Thompson JR, Matthews RJ, et al. The natural history of overactive bladder and stress urinary incontinence in older women in the community: a 3-year prospective cohort study. Neurourol Urodyn. 2006;25(7):709–16. [PubMed: 16998862]
29.
Zhang W, Song Y, He X, et al. Prevalence and risk factors of overactive bladder syndrome in Fuzhou Chinese women. Neurourol Urodyn. 2006;25(7):717–21. [PubMed: 16944449]
30.
Yu HJ, Liu CY, Lee KL, et al. Overactive bladder syndrome among community-dwelling adults in Taiwan: prevalence, correlates, perception, and treatment seeking. Urol Int. 2006;77(4):327–33. [PubMed: 17135783]
31.
Homma Y, Yamaguchi O, Hayashi K. An epidemiological survey of overactive bladder symptoms in Japan. BJU Int. 2005 Dec;96(9):1314–8. [PubMed: 16287452]
32.
MacDiarmid S, Rosenberg M. Overactive bladder in women: symptom impact and treatment expectations. Curr Med Res Opin. 2005 Sep;21(9):1413–21. [PubMed: 16197660]
33.
Zhang W, Song Y, He X, et al. Prevalence and risk factors of lower urinary tract symptoms in Fuzhou Chinese women. Eur Urol. 2005 Aug;48(2):309–13. [PubMed: 16005377]
34.
Song YF, Zhang WJ, Song J, et al. Prevalence and risk factors of urinary incontinence in Fuzhou Chinese women. Chin Med J (Engl). 2005 Jun 5;118(11):887–92. [PubMed: 15978188]
35.
Shakhatreh FM. Epidemiology of urinary incontinence in Jordanian women. Saudi Med J. 2005 May;26(5):830–5. [PubMed: 15951878]
36.
Muller N. What Americans understand and how they are affected by bladder control problems: highlights of recent nationwide consumer research. Urol Nurs. 2005 Apr;25(2):109–15. [PubMed: 15900979]
37.
Rohr G, Christensen K, Ulstrup K, et al. Reproducibility and validity of simple questions to identify urinary incontinence in elderly women. Acta Obstet Gynecol Scand. 2004 Oct;83(10):969–72. [PubMed: 15453896]
38.
Corcos J, Schick E. Prevalence of overactive bladder and incontinence in Canada. Can J Urol. 2004 Jun;11(3):2278–84. [PubMed: 15287994]
39.
Dallosso HM, McGrother CW, Matthews RJ, et al. Nutrient composition of the diet and the development of overactive bladder: a longitudinal study in women. Neurourol Urodyn. 2004;23(3):204–10. [PubMed: 15098215]
40.
Espino DV, Palmer RF, Miles TP, et al. Prevalence and severity of urinary incontinence in elderly Mexican-American women. J Am Geriatr Soc. 2003 Nov;51(11):1580–6. [PubMed: 14687387]
41.
Chen YC, Chen GD, Hu SW, et al. Is the occurrence of storage and voiding dysfunction affected by menopausal transition or associated with the normal aging process. Menopause. 2003 May-Jun;10(3):203–8. [PubMed: 12792290]
42.
Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003 May;20(6):327–36. [PubMed: 12811491]
43.
Siracusano S, Pregazzi R, d'Aloia G, et al. Prevalence of urinary incontinence in young and middle-aged women in an Italian urban area. Eur J Obstet Gynecol Reprod Biol. 2003 Apr 25;107(2):201–4. [PubMed: 12648869]
44.
Rortveit G, Daltveit AK, Hannestad YS, et al. Urinary incontinence after vaginal delivery or cesarean section. N Engl J Med. 2003 Mar 6;348(10):900–7. [PubMed: 12621134]
45.
Eva UF, Gun W, Preben K. Prevalence of urinary and fecal incontinence and symptoms of genital prolapse in women. Acta Obstet Gynecol Scand. 2003 Mar;82(3):280–6. [PubMed: 12694126]
46.
Yip SK, Chung TK. Treatment-seeking behavior in Hong Kong Chinese women with urinary symptoms. Int Urogynecol J Pelvic Floor Dysfunct. 2003 Feb;14(1):27–30. discussion 30. [PubMed: 12601513]
47.
Chen GD, Lin TL, Hu SW, et al. Prevalence and correlation of urinary incontinence and overactive bladder in Taiwanese women. Neurourol Urodyn. 2003;22(2):109–17. [PubMed: 12579627]
48.
van der Vaart CH, de Leeuw JR, Roovers JP, et al. The effect of urinary incontinence and overactive bladder symptoms on quality of life in young women. BJU Int. 2002 Oct;90(6):544–9. [PubMed: 12230614]
49.
Liu C, Andrews GR. Prevalence and incidence of urinary incontinence in the elderly: a longitudinal study in South Australia. Chin Med J (Engl). 2002 Jan;115(1):119–22. [PubMed: 11930643]
50.
Aaron R, Muliyil J, Abraham S. Medico-social dimensions of menopause: a cross-sectional study from rural south India. Natl Med J India. 2002 Jan-Feb;15(1):14–7. [PubMed: 11855585]
51.
Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001 Jun;87(9):760–6. [PubMed: 11412210]
52.
Tseng IJ, Chen YT, Chen MT, et al. Prevalence of urinary incontinence and intention to seek treatment in the elderly. J Formos Med Assoc. 2000 Oct;99(10):753–8. [PubMed: 11061069]
53.
Moller LA, Lose G, Jorgensen T. The prevalence and bothersomeness of lower urinary tract symptoms in women 40–60 years of age. Acta Obstet Gynecol Scand. 2000 Apr;79(4):298–305. [PubMed: 10746846]
54.
Ueda T, Tamaki M, Kageyama S, et al. Urinary incontinence among community-dwelling people aged 40 years or older in Japan: prevalence, risk factors, knowledge and self-perception. Int J Urol. 2000 Mar;7(3):95–103. [PubMed: 10750888]
55.
Bortolotti A, Bernardini B, Colli E, et al. Prevalence and risk factors for urinary incontinence in Italy. Eur Urol. 2000 Jan;37(1):30–5. [PubMed: 10671782]
56.
Kuh D, Cardozo L, Hardy R. Urinary incontinence in middle aged women: childhood enuresis and other lifetime risk factors in a British prospective cohort. J Epidemiol Community Health. 1999 Aug;53(8):453–8. [PMC free article: PMC1756946] [PubMed: 10562862]
57.
Simeonova Z, Milsom I, Kullendorff AM, et al. The prevalence of urinary incontinence and its influence on the quality of life in women from an urban Swedish population. Acta Obstet Gynecol Scand. 1999 Jul;78(6):546–51. [PubMed: 10376867]
58.
Kay L, Stigsby B, Brasso K, et al. Lower urinary tract symptoms--a population survey using the Danish Prostatic Symptom Score (DAN-PSS) questionnaire. Scand J Urol Nephrol. 1999 Apr;33(2):94–9. [PubMed: 10360448]
59.
Koyama W, Koyanagi A, Mihara S, et al. Prevalence and conditions of urinary incontinence among the elderly. Methods Inf Med. 1998 Jun;37(2):151–5. [PubMed: 9656656]
60.
Schulman C, Claes H, Matthijs J. Urinary incontinence in Belgium: a population-based epidemiological survey. Eur Urol. 1997;32(3):315–20. [PubMed: 9358220]
61.
Brieger GM, Mongelli M, Hin LY, et al. The epidemiology of urinary dysfunction in Chinese women. Int Urogynecol J Pelvic Floor Dysfunct. 1997;8(4):191–5. [PubMed: 9449294]
62.
Bogren MA, Hvarfwen E, Fridlund B. Urinary incontinence among a 65-year old Swedish population: medical history and psychosocial consequences. Vard Nord Utveckl Forsk. 1997 Winter;17(4):14–7. [PubMed: 9464154]
63.
Brieger GM, Yip SK, Hin LY, et al. The prevalence of urinary dysfunction in Hong Kong Chinese women. Obstet Gynecol. 1996 Dec;88(6):1041–4. [PubMed: 8942850]
64.
Nygaard IE, Lemke JH. Urinary incontinence in rural older women: prevalence, incidence and remission. J Am Geriatr Soc. 1996 Sep;44(9):1049–54. [PubMed: 8790229]
65.
Lara C, Nacey J. Ethnic differences between Maori, Pacific Island and European New Zealand women in prevalence and attitudes to urinary incontinence. N Z Med J. 1994 Sep 28;107(986 Pt 1):374–6. [PubMed: 7619104]
66.
Ju CC, Swan LK, Merriman A, et al. Urinary incontinence among the elderly people of Singapore. Age Ageing. 1991 Jul;20(4):262–6. [PubMed: 1927732]
67.
Hording U, Pedersen KH, Sidenius K, et al. Urinary incontinence in 45-year-old women. An epidemiological survey. Scand J Urol Nephrol. 1986;20(3):183–6. [PubMed: 3787195]
68.
Iosif CS, Bekassy Z. Prevalence of genito-urinary symptoms in the late menopause. Acta Obstet Gynecol Scand. 1984;63(3):257–60. [PubMed: 6730943]
69.
Danforth KN, Shah AD, Townsend MK, et al. Physical activity and urinary incontinence among healthy, older women. Obstet Gynecol. 2007 Mar;109(3):721–7. [PubMed: 17329526]
70.
Ege E, Akin B, Altuntug K, et al. Prevalence of urinary incontinence in the 12-month postpartum period and related risk factors in Turkey. Urol Int. 2008;80(4):355–61. [PubMed: 18587244]
71.
Hall SA, Cinar A, Link CL, et al. Do urological symptoms cluster among women? Results from the Boston Area Community Health Survey. BJU Int. 2008 May;101(10):1257–66. [PubMed: 18419699]
72.
Minassian VA, Stewart WF, Wood GC. Urinary incontinence in women: variation in prevalence estimates and risk factors. Obstet Gynecol. 2008 Feb;111(2 Pt 1):324–31. [PubMed: 18238969]
73.
Tikkinen KA, Auvinen A, Tiitinen A, et al. Reproductive factors associated with nocturia and urinary urgency in women: a population-based study in Finland. Am J Obstet Gynecol. 2008 Aug;199(2):153 e1–12. [PubMed: 18486094]
74.
Townsend MK, Curhan GC, Resnick NM, et al. BMI, waist circumference, and incident urinary incontinence in older women. Obesity (Silver Spring). 2008 Apr;16(4):881–6. [PubMed: 18379564]
75.
Wesnes SL, Rortveit G, Bo K, et al. Urinary incontinence during pregnancy. Obstet Gynecol. 2007 Apr;109(4):922–8. [PubMed: 17400855]
76.
Hannestad YS, Rortveit G, Sandvik H, et al. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trondelag. J Clin Epidemiol. 2000 Nov;53(11):1150–7. [PubMed: 11106889]
77.
Herzog AR, Diokno AC, Brown MB, et al. Two-year incidence, remission, and change patterns of urinary incontinence in noninstitutionalized older adults. J Gerontol. 1990 Mar;45(2):M67–74. [PubMed: 2313045]
78.
Perry S, Shaw C, Assassa P, et al. An epidemiological study to establish the prevalence of urinary symptoms and felt need in the community: the Leicestershire MRC Incontinence Study. Leicestershire MRC Incontinence Study Team. J Public Health Med. 2000 Sep;22(3):427–34. [PubMed: 11077920]
79.
Yarnell JW, Voyle GJ, Richards CJ, et al. The prevalence and severity of urinary incontinence in women. J Epidemiol Community Health. 1981 Mar;35(1):71–4. [PMC free article: PMC1052123] [PubMed: 7264536]
80.
Zhu L, Lang J, Wang H, et al. The prevalence of and potential risk factors for female urinary incontinence in Beijing, China. Menopause. 2008 May-Jun;15(3):566–9. [PubMed: 18467955]
81.
Nuotio M, Tammela TL, Luukkaala T, et al. Urgency and urge incontinence in an older population: ten-year changes and their association with mortality. Aging Clin Exp Res. 2002 Oct;14(5):412–9. [PubMed: 12602577]
82.
Zinner N, Tuttle J, Marks L. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J Urol. 2005 Sep;23(4):248–52. [PubMed: 16096831]
83.
Sand PK, Miklos J, Ritter H, et al. A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women. Int Urogynecol J Pelvic Floor Dysfunct. 2004 Jul-Aug;15(4):243–8. [PubMed: 15517668]
84.
Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003 Jun;78(6):687–95. [PubMed: 12934777]
85.
Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol. 2002 Aug;168(2):580–6. [PubMed: 12131314]
86.
Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). Curr Med Res Opin. 2002;18(4):177–84. [PubMed: 12201616]
87.
Davila GW, Daugherty CA, Sanders SW. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol. 2001 Jul;166(1):140–5. [PubMed: 11435842]
88.
Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003 Aug;62(2):237–42. [PubMed: 12893326]
89.
Giannitsas K, Perimenis P, Athanasopoulos A, et al. Comparison of the efficacy of tolterodine and oxybutynin in different urodynamic severity grades of idiopathic detrusor overactivity. Eur Urol. 2004 Dec;46(6):776–82. discussion 782–3. [PubMed: 15548447]
90.
Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol. 2003 May;20(6):392–9. [PubMed: 12811500]
91.
Abrams P, Freeman R, Anderstrom C, et al. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol. 1998 Jun;81(6):801–10. [PubMed: 9666761]
92.
Homma Y, Koyama N. Minimal clinically important change in urinary incontinence detected by a quality of life assessment tool in overactive bladder syndrome with urge incontinence. Neurourol Urodyn. 2006;25(3):228–35. [PubMed: 16532466]
93.
Wang AC, Chih SY, Chen MC. Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial. Urology. 2006 Nov;68(5):999–1004. [PubMed: 17113893]
94.
Lee JG, Hong JY, Choo MS, et al. Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder. Int J Urol. 2002 May;9(5):247–52. [PubMed: 12060436]
95.
Nitti VW, Dmochowski R, Sand PK, et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol. 2007 Dec;178(6):2488–94. [PubMed: 17937959]
96.
Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007 Oct;52(4):1204–12. [PubMed: 17651893]
97.
Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004 Feb;93(3):303–10. [PubMed: 14764127]
98.
Yamaguchi O, Marui E, Kakizaki H, et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int. 2007 Sep;100(3):579–87. [PubMed: 17669143]
99.
Chapple CR, Fianu-Jonsson A, Indig M, et al. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. Eur Urol. 2007 Oct;52(4):1195–203. [PubMed: 17574730]
100.
Hill S, Khullar V, Wyndaele JJ, et al. Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. Int Urogynecol J Pelvic Floor Dysfunct. 2006 May;17(3):239–47. [PubMed: 15999217]
101.
Zinner N, Susset J, Gittelman M, et al. Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. Int J Clin Pract. 2006 Jan;60(1):119–26. [PubMed: 16409440]
102.
Steers W, Corcos J, Foote J, et al. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU Int. 2005 Mar;95(4):580–6. [PubMed: 15705084]
103.
Staskin D, Sand P, Zinner N, et al. Once; daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. J Urol. 2007 Sep;178(3 Pt 1):978–83. discussion 983–4. [PubMed: 17632131]
104.
Rudy D, Cline K, Harris R, et al. Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU Int. 2006 Mar;97(3):540–6. [PubMed: 16469022]
105.
Dmochowski RR, Sand PK, Zinner NR, et al. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology. 2008 Mar;71(3):449–54. [PubMed: 18342185]
106.
Zinner N, Gittelman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol. 2004 Jun;171(6 Pt 1):2311–5. quiz 2435. [PubMed: 15126811]
107.
Cardozo L, Rekers H, Tapp A, et al. Oestriol in the treatment of postmenopausal urgency: a multicentre study. Maturitas. 1993 Dec;18(1):47–53. [PubMed: 8107615]
108.
Lose G, Englev E. Oestradiol-releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms. BJOG. 2000 Aug;107(8):1029–34. [PubMed: 10955437]
109.
Molander U, Milsom I, Ekelund P, et al. A health care program for the investigation and treatment of elderly women with urinary incontinence and related urogenital symptoms. Acta Obstet Gynecol Scand. 1991;70(2):137–42. [PubMed: 1882660]
110.
Groenendijk PM, Lycklama a Nyeholt AA, Heesakkers JP, et al. Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence. BJU Int. 2008 Feb;101(3):325–9. [PubMed: 18070199]
111.
Janknegt RA, Hassouna MM, Siegel SW, et al. Long-term effectiveness of sacral nerve stimulation for refractory urge incontinence. Eur Urol. 2001 Jan;39(1):101–6. [PubMed: 11173947]
112.
Kessler TM, Buchser E, Meyer S, et al. Sacral neuromodulation for refractory lower urinary tract dysfunction: results of a nationwide registry in Switzerland. Eur Urol. 2007 May;51(5):1357–63. [PubMed: 17113216]
113.
Koldewijn EL, Rosier PF, Meuleman EJ, et al. Predictors of success with neuromodulation in lower urinary tract dysfunction: results of trial stimulation in 100 patients. J Urol. 1994 Dec;152(6 Pt 1):2071–5. [PubMed: 7966677]
114.
Siegel SW, Catanzaro F, Dijkema HE, et al. Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology. 2000 Dec 4;56(6 Suppl 1):87–91. [PubMed: 11114569]
115.
van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol. 2007 Nov;178(5):2029–34. [PubMed: 17869298]
116.
Fossberg E, Sorensen S, Ruutu M, et al. Maximal electrical stimulation in the treatment of unstable detrusor and urge incontinence. Eur Urol. 1990;18(2):120–3. [PubMed: 2226580]
117.
Schmid DM, Sauermann P, Werner M, et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol. 2006 Jul;176(1):177–85. [PubMed: 16753396]
118.
Korda A, Krieger M, Hunter P. The use of prolonged bladder distension in the treatment of intractable urinary incontinence in females with detrusor instability. Aust N Z J Obstet Gynaecol. 1987 May;27(2):155–7. [PubMed: 3675443]
119.
Sutherland SE, Lavers A, Carlson A, et al. Sacral nerve stimulation for voiding dysfunction: One institution's 11-year experience. Neurourol Urodyn. 2007;26(1):19–28. discussion 36. [PubMed: 17078071]
120.
van Voskuilen AC, Oerlemans DJ, Weil EH, et al. Long term results of neuromodulation by sacral nerve stimulation for lower urinary tract symptoms: a retrospective single center study. Eur Urol. 2006 Feb;49(2):366–72. [PubMed: 16413105]
121.
Mundy AR. Long-term results of bladder transection for urge incontinence. Br J Urol. 1983 Dec;55(6):642–4. [PubMed: 6652432]
122.
Spinelli M, Bertapelle P, Cappellano F, et al. Chronic sacral neuromodulation in patients with lower urinary tract symptoms: results from a national register. J Urol. 2001 Aug;166(2):541–5. [PubMed: 11458063]
123.
Hassouna MM, Siegel SW, Nyeholt AA, et al. Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety. J Urol. 2000 Jun;163(6):1849–54. [PubMed: 10799197]
124.
Schmidt RA, Jonas U, Oleson KA, et al. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group. J Urol. 1999 Aug;162(2):352–7. [PubMed: 10411037]
125.
O'Reilly BA, Fynes M, Achtari C, et al. A prospective randomised double-blind controlled trial evaluating the effect of trans-sacral magnetic stimulation in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 2008 Apr;19(4):497–502. [PubMed: 17932613]
126.
Enzelsberger H, Helmer H, Kurz C. Intravesical instillation of oxybutynin in women with idiopathic detrusor instability: a randomised trial. Br J Obstet Gynaecol. 1995 Nov;102(11):929–30. [PubMed: 8534633]
127.
Rios LA, Panhoca R, Mattos D Jr, et al. Intravesical resiniferatoxin for the treatment of women with idiopathic detrusor overactivity and urgency incontinence: A single dose, 4 weeks, double-blind, randomized, placebo controlled trial. Neurourol Urodyn. 2007;26(6):773–8. [PubMed: 17638305]
128.
Duthie J, Wilson DI, Herbison GP, et al. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database of Systematic Reviews. 2007;2007(3) [PubMed: 17636801]
129.
Frewen WK. A reassessment of bladder training in detrusor dysfunction in the female. Br J Urol. 1982 Aug;54(4):372–3. [PubMed: 7116102]
130.
Dorey G, Sultan H, Eckford SD, et al. Pelvic floor muscle exercises and urge suppression techniques in women with urge urinary incontinence: a retrospective study from a dedicated urogynaecology clinic. Journal of the Association of Chartered Physiotherapists in Women's Health. 2006;99(Autumn):43–8.
131.
Millard RJ, Oldenburg BF. The symptomatic, urodynamic and psychodynamic results of bladder reeducation programs. J Urol. 1983 Oct;130(4):715–9. [PubMed: 6887404]
132.
Dowd T, Kolcaba K, Steiner R. The addition of coaching to cognitive strategies: interventions for persons with compromised urinary bladder syndrome. J Wound Ostomy Continence Nurs. 2003 Mar;30(2):90–9. [PubMed: 12658237]
133.
Jarvis GJ, Millar DR. Controlled trial of bladder drill for detrusor instability. Br Med J. 1980 Nov 15;281(6251):1322–3. [PMC free article: PMC1714748] [PubMed: 7002250]
134.
Wyman JF, Fantl JA, McClish DK, et al. Comparative efficacy of behavioral interventions in the management of female urinary incontinence. Continence Program for Women Research Group. Am J Obstet Gynecol. 1998 Oct;179(4):999–1007. [PubMed: 9790388]
135.
Burgio KL, Goode PS, Locher JL, et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. JAMA. 2002 Nov 13;288(18):2293–9. [PubMed: 12425706]
136.
Bryant CM, Dowell CJ, Fairbrother G. Caffeine reduction education to improve urinary symptoms. Br J Nurs. 2002 Apr 25-May 8;11(8):560–5. [PubMed: 11979209]
137.
Emmons SL, Otto L. Acupuncture for overactive bladder: a randomized controlled trial. Obstet Gynecol. 2005 Jul;106(1):138–43. [PubMed: 15994629]
138.
Mak HL, Cheon WC, Wong T, et al. Randomized controlled trial of foot reflexology for patients with symptomatic idiopathic detrusor overactivity. Int Urogynecol J Pelvic Floor Dysfunct. 2007 Jun;18(6):653–8. [PubMed: 17003953]
139.
Freeman RM, Baxby K. Hypnotherapy for incontinence caused by the unstable detrusor. Br Med J (Clin Res Ed). 1982 Jun 19;284(6332):1831–4. [PMC free article: PMC1498778] [PubMed: 6805716]
140.
Swift S, Garely A, Dimpfl T, et al. A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 2003 Feb;14(1):50–4. discussion 54–5. [PubMed: 12601517]
141.
Van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology. 2001 Mar;57(3):414–21. [PubMed: 11248608]
142.
Chapple CR, Van Kerrebroeck PE, Junemann KP, et al. Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU Int. 2008 Nov;102(9):1128–32. [PubMed: 18647298]
143.
Burgio KL, Locher JL, Goode PS, et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA. 1998 Dec 16;280(23):1995–2000. [PubMed: 9863850]
144.
Burgio KL, Locher JL, Roth DL, et al. Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women. J Gerontol B Psychol Sci Soc Sci. 2001 Jan;56(1):P46–51. [PubMed: 11192337]
145.
Goode PS, Burgio KL, Locher JL, et al. Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women. J Am Geriatr Soc. 2002 May;50(5):808–16. [PubMed: 12028165]
146.
Colombo M, Zanetta G, Scalambrino S, et al. Oxybutynin and bladder training in the management of female urge urinary incontinence: a randomized study. Int Urogynecol J. 1995;6(2):63–67.
147.
Diokno A, Yuhico M Jr. Preference, compliance and initial outcome of therapeutic options chosen by female patients with urinary incontinence. J Urol. 1995 Nov;154(5):1727–30. discussion 1731. [PubMed: 7563333]
148.
Macaulay AJ, Stern RS, Holmes DM, et al. Micturition and the mind: psychological factors in the aetiology and treatment of urinary symptoms in women. Br Med J (Clin Res Ed). 1987 Feb 28;294(6571):540–3. [PMC free article: PMC1245577] [PubMed: 3103764]
149.
Jarvis GJ. A controlled trial of bladder drill and drug therapy in the management of detrusor instability. Br J Urol. 1981 Dec;53(6):565–6. [PubMed: 7032639]
150.
Song C, Park JT, Heo KO, et al. Effects of bladder training and/or tolterodine in female patients with overactive bladder syndrome: a prospective, randomized study. J Korean Med Sci. 2006 Dec;21(6):1060–3. [PMC free article: PMC2721929] [PubMed: 17179687]
151.
Mattiasson A, Blaakaer J, Hoye K, et al. Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. BJU Int. 2003 Jan;91(1):54–60. [PubMed: 12614251]
152.
Burgio KL, Kraus SR, Menefee S, et al. Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial. Ann Intern Med. 2008 Aug 5;149(3):161–9. [PMC free article: PMC3201984] [PubMed: 18678843]
153.
Chancellor MB, Kianifard F, Beamer E, et al. A comparison of the efficacy of darifenacin alone vs. darifenacin plus a Behavioural Modification Programme upon the symptoms of overactive bladder. Int J Clin Pract. 2008 Apr;62(4):606–13. [PMC free article: PMC2325270] [PubMed: 18324952]
154.
Millard RJ. Clinical efficacy of tolterodine with or without a simplified pelvic floor exercise regimen. Neurourol Urodyn. 2004;23(1):48–53. [PubMed: 14694457]
155.
Herschorn S, Becker D, Miller E, et al. Impact of a health education intervention in overactive bladder patients. Can J Urol. 2004 Dec;11(6):2430–7. [PubMed: 15636668]
156.
Layton D, Pearce GL, Shakir SA. Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring. Drug Saf. 2001;24(9):703–13. [PubMed: 11522122]
157.
Michel MC, Schneider T, Krege S, et al. Does gender or age affect the efficacy and safety of tolterodine? J Urol. 2002 Sep;168(3):1027–31. [PubMed: 12187215]
158.
Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc. 2002 May;50(5):799–807. [PubMed: 12028164]
159.
Hill S, Elhilali M, Millard RJ, et al. Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study. Curr Med Res Opin. 2007 Nov;23(11):2697–704. [PubMed: 17892634]
160.
Elinoff V, Bavendam T, Glasser DB, et al. Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial. Int J Clin Pract. 2006 Jun;60(6):745–51. [PubMed: 16805763]
161.
Staskin DR, Harnett MD. Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Curr Urol Rep. 2004 Dec;5(6):423–6. [PubMed: 15541209]
162.
Jacquetin B, Wyndaele J. Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder. Eur J Obstet Gynecol Reprod Biol. 2001 Sep;98(1):97–102. [PubMed: 11516807]
163.
Appell RA, Abrams P, Drutz HP, et al. Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. World J Urol. 2001 Apr;19(2):141–7. [PubMed: 11374317]
164.
Anderson RU, MacDiarmid S, Kell S, et al. Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 2006 Sep;17(5):502–11. [PubMed: 16724169]
165.
Gleason DM, Susset J, White C, et al. Evaluation of a new once-daily formulation of oxbutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group. Urology. 1999 Sep;54(3):420–3. [PubMed: 10475346]
166.
Michel MC, de la Rosette JJ, Piro M, et al. Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder. Eur Urol. 2005 Jul;48(1):110–5. [PubMed: 15967259]
167.
Garely AD, Lucente V, Vapnek J, et al. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes. Ann Pharmacother. 2007 Mar;41(3):391–8. [PubMed: 17341526]
168.
Landis JR, Kaplan S, Swift S, et al. Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. J Urol. 2004 Feb;171(2 Pt 1):752–6. [PubMed: 14713803]
169.
Kreder KJ Jr, Brubaker L, Mainprize T. Tolterodine is equally effective in patients with mixed incontinence and those with urge incontinence alone. BJU Int. 2003 Sep;92(4):418–21. [PubMed: 12930432]
170.
Steers WD, Herschorn S, Kreder KJ, et al. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU Int. 2007 Aug;100(2):337–45. [PubMed: 17511767]
171.
Malone-Lee J, Henshaw DJ, Cummings K. Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response. BJU Int. 2003 Sep;92(4):415–7. [PubMed: 12930431]
172.
Salvatore S, Serati M, Digesu GA, et al. Efficacy of tolterodine in relation to different urodynamic findings of detrusor overactivity. Int Urogynecol J Pelvic Floor Dysfunct. 2008 May;19(5):701–4. [PubMed: 18066482]
173.
Serati M, Salvatore S, Uccella S, et al. Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy. Eur Urol. 2008 Oct;54(4):911–5. [PubMed: 18036728]
174.
Freeman R, Hill S, Millard R, et al. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstet Gynecol. 2003 Sep;102(3):605–11. [PubMed: 12962951]
175.
Varadharajan S, Jumadilova Z, Girase P, et al. Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder. Am J Manag Care. 2005 Jul;11(4 Suppl):S140–9. [PubMed: 16161387]
176.
Hall JA, Nelson MA, Meyer JW, et al. Costs and resources associated with the treatment of overactive bladder using retrospective medical care claims data. Manag Care Interface. 2001 Aug;14(8):69–75. [PubMed: 11517841]
177.
Jensen GA, Zhou Z, Torigoe Y. Medical care of overactive bladder in elderly patients. Journal of Aging & Pharmacotherapy. 2003;13(1):13–27.
178.
Nitz NM, Jumadilova Z, Darkow T, et al. Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates. Am J Manag Care. 2005 Jul;11(4 Suppl):S130–9. [PubMed: 16161386]
179.
Hu TW, Wagner TH, Bentkover JD, et al. Estimated economic costs of overactive bladder in the United States. Urology. 2003 Jun;61(6):1123–8. [PubMed: 12809878]
180.
Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–78. [PubMed: 11857671]
181.
Gardyn R. Detrol. Advertising Age. 1999 June;28:1999.
182.
Fisher JA. Medical Research for Hire: The Political Economy of Pharmaceutical Clinical Trials. New Brunswick, NJ: Rutgers University Press; 2009.
183.
Kassirer JP. On the Take: How America's Complicity with Big Business Can Endanger Your Health. New York: Oxford University Press; 2005.
184.
Ronald L. Empowered to Consume: Direct-to-consumer advertising and pharmaceutical governance. Troy, NY: Rensselaer Polytechnic Institute; 2006.
185.
Petersen M. Our Daily Meds: How the Pharmaceutical Companies Transformed Themselves into Slick Marketing Machines and Hooked the Nation on Prescription Drugs. New York: Farrar, Straus and Giroux; 2008.
186.
Pfizer. Pfizer Achieves Key 2006 Financial Targetes. 2007. [updated 2007; cited 2009 January 8]; Available from: http://www​.prnewswire​.com/cgi-bin/stories​.pl?ACCT=104&STORY=​/www/story/01-22-2007​/0004509853&EDATE=
187.
Bren L. Controlling Urinary Incontinence. FDA Consumer Magazine. 2005 Sept-Oct
188.
Brown JS, Vittinghoff E, Wyman JF, et al. Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc. 2000 Jul;48(7):721–5. [PubMed: 10894308]
189.
Darkow T, Fontes CL, Williamson TE. Costs associated with the management of overactive bladder and related comorbidities. Pharmacotherapy. 2005 Apr;25(4):511–9. [PubMed: 15977912]
190.
Matchar DB, Myers ER, Barber MW, et al. Management of uterine fibroids. Evid Rep Technol Assess (Summ). 2001 Jan;34:1–6. [PubMed: 11236283]
191.
Schulz KF, Chalmers I, Grimes DA, et al. Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals. JAMA. 1994 Jul 13;272(2):125–8. [PubMed: 8015122]
192.
Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995 Feb 1;273(5):408–12. [PubMed: 7823387]
193.
Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001 Apr 17;134(8):663–94. [PubMed: 11304107]
194.
West S, King V, Carey TS, et al. Systems to rate the strength of scientific evidence. Evid Rep Technol Assess (Summ). 2002 Mar;47:1–11. [PubMed: 11979732]
195.
Viswanathan M, Hartmann K, McKoy N, et al. Management of Uterine Fibroids: An Update of the Evidence. Evidence Report/Technology Assessment No. 154 (Prepared by RTI International-University of North Carolina Evidence-based Practice Center under Contract No. 290-02-0016. AHRQ Publication No. 07–E011. Rockville, MD: Agency for Healthcare Research and Quality; 2007.
196.
Shamliyan T, Wyman J, Bliss DZ, et al. Prevention of urinary and fecal incontinence in adults. Evid Rep Technol Assess (Full Rep). 2007 Dec;(161):1–379. [PubMed: 18457475]
197.
Wilkinson E. Urinary incontinence in women. Nurs Times. 2006 Nov 28-Dec 4;102(48):23–4. [PubMed: 17193773]
198.
Abrams P, Cardozo L, Chapple C, et al. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Int J Urol. 2006 Jun;13(6):692–8. [PubMed: 16834644]
199.
Anderson RU, Mobley D, Blank B, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol. 1999 Jun;161(6):1809–12. [PubMed: 10332441]
200.
Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc. 2001 Apr;76(4):358–63. [PubMed: 11322350]
201.
Arruda RM, Castro RA, Sousa GC, et al. Prospective randomized comparison of oxybutynin, functional electrostimulation, and pelvic floor training for treatment of detrusor overactivity in women. Int Urogynecol J Pelvic Floor Dysfunct. 2008 Aug;19(8):1055–61. [PubMed: 18330483]
202.
Barkin J, Corcos J, Radomski S, et al. A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. Clin Ther. 2004 Jul;26(7):1026–36. [PubMed: 15336467]
203.
Bemelmans BL, Kiemeney LA, Debruyne FM. Low-dose oxybutynin for the treatment of urge incontinence: good efficacy and few side effects. Eur Urol. 2000 Jun;37(6):709–13. [PubMed: 10828672]
204.
Boone TB, Kusek JW, Nyberg LM, et al. Treatment patterns and associated symptom improvement during six months of care for overactive bladder: a prospective, observational study. Clin Ther. 2002 Mar;24(3):397–408. [PubMed: 11952023]
205.
Capo JP Jr, Laramee C, Lucente V, et al. Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial. Int J Clin Pract. 2008 Jan;62(1):39–46. [PubMed: 18036164]
206.
Cardozo L, Hessdorfer E, Milani R, et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int. 2008 Nov;102(9):1120–7. [PubMed: 18990175]
207.
Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):1919–24. [PubMed: 15540755]
208.
Chancellor MB, Zinner N, Whitmore K, et al. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. Clin Ther. 2008 Oct;30(10):1766–81. [PubMed: 19014833]
209.
Chancellor M, Freedman S, Mitcheson HD, et al. Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clinical Drug Investigation. 2000;19(2):83–91.
210.
Chapple C, DuBeau C, Ebinger U, et al. Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Curr Med Res Opin. 2007 Oct;23(10):2347–58. [PubMed: 17706004]
211.
Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol. 2005 Sep;48(3):464–70. [PubMed: 15990220]
212.
Choo MS, Doo CK, Lee KS. Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study). Int J Clin Pract. 2008 Feb;62(2):191–6. [PubMed: 18067558]
213.
Chu FM, Dmochowski RR, Lama DJ, et al. Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial. Am J Obstet Gynecol. 2005 Jun;192(6):1849–54. discussion 1854–5. [PubMed: 15970828]
214.
Diokno A, Sand P, Labasky R, et al. Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study. Int Urol Nephrol. 2002;34(1):43–9. [PubMed: 12549638]
215.
Dmochowski R, Kreder K, MacDiarmid S, et al. The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder. BJU Int. 2007 Jul;100(1):107–10. [PubMed: 17552957]
216.
Drutz HP, Appell RA, Gleason D, et al. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 1999;10(5):283–9. [PubMed: 10543335]
217.
Dwyer P, Kelleher C, Young J, et al. Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study. Neurourol Urodyn. 2008;27(6):540–7. [PubMed: 18663723]
218.
Garely AD, Kaufman JM, Sand PK, et al. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther. 2006 Nov;28(11):1935–46. [PubMed: 17213014]
219.
Haab F, Corcos J, Siami P, et al. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int. 2006 Nov;98(5):1025–32. [PubMed: 16879437]
220.
Haab F, Cardozo L, Chapple C, et al. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol. 2005 Mar;47(3):376–84. [PubMed: 15716204]
221.
Jonas U, Hofner K, Madersbacher H, et al. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. World J Urol. 1997;15(2):144–51. [PubMed: 9144906]
222.
Karram MM, Toglia MR, Serels SR, et al. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology. 2009 Jan;73(1):14–8. [PubMed: 18995887]
223.
Kelleher CJ, Kreder KJ, Pleil AM, et al. Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care. 2002 Dec;8(19 Suppl):S616–30. [PubMed: 12516956]
224.
Kelleher CJ, Reese PR, Pleil AM, et al. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care. 2002 Dec;8(19 Suppl):S608–15. [PubMed: 12516955]
225.
Kelleher CJ, Cardozo L, Chapple CR, et al. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int. 2005 Jan;95(1):81–5. [PubMed: 15638900]
226.
Koonings PP, Bergman A. Urethral pressure changes in women with detrusor instability. Bladder or urethral pathologic process? Urology. 1991 Jun;37(6):540–2. [PubMed: 2038787]
227.
Kreder K, Mayne C, Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol. 2002 Jun;41(6):588–95. [PubMed: 12074774]
228.
Leung HY, Yip SK, Cheon C, et al. A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder. BJU Int. 2002 Sep;90(4):375–80. [PubMed: 12175392]
229.
Mallett V, Burks D, Garely AD, et al. Solifenacin treatment for overactive bladder in black patients: patient-reported symptom bother and health-related quality of life outcomes. Curr Med Res Opin. 2007 Apr;23(4):821–31. [PubMed: 17407639]
230.
Messelink EJ. Treatment of the overactive bladder with tolterodine, a new muscarinic receptor antagonist. BJU Int. 1999 Mar;83( Suppl 2):48–52. [PubMed: 10210605]
231.
Michel MC, Wetterauer U, Vogel M, et al. Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study. Drug Saf. 2008;31(6):505–14. [PubMed: 18484784]
232.
Michel MC, Oelke M, Goepel M, et al. Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients. Neurourol Urodyn. 2007;26(2):190–5. [PubMed: 17096320]
233.
Millard R, Tuttle J, Moore K, et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol. 1999 May;161(5):1551–5. [PubMed: 10210394]
234.
Minassian VA, Ross S, Sumabat O, et al. Randomized trial of oxybutynin extended versus immediate release for women aged 65 and older with overactive bladder: lessons learned from conducting a trial. J Obstet Gynaecol Can. 2007 Sep;29(9):726–32. [PubMed: 17825137]
235.
Moore KH, Sutherst JR. Response to treatment of detrusor instability in relation to psychoneurotic status. Br J Urol. 1990 Nov;66(5):486–90. [PubMed: 2249116]
236.
Moore KH, Hay DM, Imrie AE, et al. Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability. Br J Urol. 1990 Nov;66(5):479–85. [PubMed: 2249115]
237.
Preik M, Albrecht D, O'Connell M, et al. Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: severity-dependent treatment of the overactive bladder. BJU Int. 2004 Oct;94(6):821–7. [PubMed: 15476516]
238.
Rentzhog L, Stanton SL, Cardozo L, et al. Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. Br J Urol. 1998 Jan;81(1):42–8. [PubMed: 9467475]
239.
Roberts R, Bavendam T, Glasser DB, et al. Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial. Int J Clin Pract. 2006 Jun;60(6):752–8. [PubMed: 16805764]
240.
Robinson D, Cardozo L, Terpstra G, et al. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. BJU Int. 2007 Oct;100(4):840–5. [PubMed: 17822465]
241.
Rogers R, Bachmann G, Jumadilova Z, et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. Int Urogynecol J Pelvic Floor Dysfunct. 2008 Nov;19(11):1551–7. [PubMed: 18685795]
242.
Rudy D, Cline K, Harris R, et al. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology. 2006 Feb;67(2):275–80. [PubMed: 16461077]
243.
Salvatore S, Serati M, Ghezzi F, et al. Efficacy of tolterodine in women with detrusor overactivity and anterior vaginal wall prolapse: is it the same? BJOG. 2007 Nov;114(11):1436–8. [PubMed: 17877779]
244.
Salvatore S, Khullar V, Cardozo L, et al. Long-term prospective randomized study comparing two different regimens of oxybutynin as a treatment for detrusor overactivity. Eur J Obstet Gynecol Reprod Biol. 2005 Apr 1;119(2):237–41. [PubMed: 15808387]
245.
Sand P, Zinner N, Newman D, et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int. 2007 Apr;99(4):836–44. [PubMed: 17187655]
246.
Sand PK, Goldberg RP, Dmochowski RR, et al. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Am J Obstet Gynecol. 2006 Dec;195(6):1730–5. [PubMed: 17132474]
247.
Tseng LH, Wang AC, Chang YL, et al. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome. Neurourol Urodyn. 2009;28(1):47–51. [PubMed: 19089890]
248.
Versi E, Appell R, Mobley D, et al. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet Gynecol. 2000 May;95(5):718–21. [PubMed: 10775736]
249.
Wang PS, Levin R, Zhao SZ, et al. Urinary antispasmodic use and the risks of ventricular arrhythmia and sudden death in older patients. J Am Geriatr Soc. 2002 Jan;50(1):117–24. [PubMed: 12028256]
250.
Zinner N, Noe L, Rasouliyan L, et al. Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER. Curr Med Res Opin. 2008 Jun;24(6):1583–91. [PubMed: 18423103]
251.
Burgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc. 2000 Apr;48(4):370–4. [PubMed: 10798461]
252.
Fantl JA, Hurt WG, Dunn LJ. Detrusor instability syndrome: the use of bladder retraining drills with and without anticholinergics. Am J Obstet Gynecol. 1981 Aug 15;140(8):885–90. [PubMed: 7270599]
253.
Ghei M, Miller R, Malone-Lee J. Case series data to encourage randomized trials of bladder retraining compared to antimuscarinic agents. J Urol. 2006 Apr;175(4):1411–5. discussion 1415–6. [PubMed: 16516010]
254.
Lauti M, Herbison P, Hay-Smith J, et al. Anticholinergic drugs, bladder retraining and their combination for urge urinary incontinence: a pilot randomised trial. Int Urogynecol J Pelvic Floor Dysfunct. 2008 Nov;19(11):1533–43. [PubMed: 18654731]
255.
Szonyi G, Collas DM, Ding YY, et al. Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. Age Ageing. 1995 Jul;24(4):287–91. [PubMed: 7484484]
256.
Oerlemans DJ, van Kerrebroeck PE. Sacral nerve stimulation for neuromodulation of the lower urinary tract. Neurourol Urodyn. 2008;27(1):28–33. [PubMed: 17563110]
257.
Cooperberg MR, Stoller ML. Percutaneous neuromodulation. Urol Clin North Am. 2005 Feb;32(1):71–8. vii. [PubMed: 15698879]
258.
van Balken MR, Vandoninck V, Gisolf KW, et al. Posterior tibial nerve stimulation as neuromodulative treatment of lower urinary tract dysfunction. J Urol. 2001 Sep;166(3):914–8. [PubMed: 11490245]
259.
Vandoninck V, Van Balken MR, Finazzi Agro E, et al. Posterior tibial nerve stimulation in the treatment of urge incontinence. Neurourol Urodyn. 2003;22(1):17–23. [PubMed: 12478596]
260.
McGuire EJ, Zhang SC, Horwinski ER, et al. Treatment of motor and sensory detrusor instability by electrical stimulation. J Urol. 1983 Jan;129(1):78–9. [PubMed: 6600794]
261.
Goldberg RP, Sand PK. Electromagnetic pelvic floor stimulation: applications for the gynecologist. Obstet Gynecol Surv. 2000 Nov;55(11):715–20. [PubMed: 11075736]
262.
Giannantoni A, Di Stasi SM, Stephen RL, et al. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol. 2004 Jul;172(1):240–3. [PubMed: 15201783]
263.
Karsenty G, Reitz A, Lindemann G, et al. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology. 2006 Dec;68(6):1193–7. [PubMed: 17141831]
264.
Kuo HC. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology. 2004 May;63(5):868–72. [PubMed: 15134967]
265.
Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol. 2008 Jul;180(1):217–22. [PMC free article: PMC2597793] [PubMed: 18499184]
266.
McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993 Mar;31(3):247–63. [PubMed: 8450681]
267.
Wagner TH, Patrick DL, Bavendam TG, et al. Quality of life of persons with urinary incontinence: development of a new measure. Urology. 1996 Jan;47(1):67–71. discussion 71–2. [PubMed: 8560665]
268.
Sorensen SS, Nielsen JB, Norgaard JP, et al. Changes in bladder volumes with repetition of water cystometry. Urol Res. 1984;12(4):205–8. [PubMed: 6495446]
269.
Wang AC, Wang YY, Chen MC. Single-blind, randomized trial of pelvic floor muscle training, biofeedback-assisted pelvic floor muscle training, and electrical stimulation in the management of overactive bladder. Urology. 2004 Jan;63(1):61–6. [PubMed: 14751349]
270.
Nabi G, Cody JD, Ellis G, et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006(4):CD003781. [PubMed: 17054185]
271.
Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008 Sep;54(3):543–62. [PubMed: 18599186]
272.
D'Souza AO, Smith MJ, Miller LA, et al. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm. 2008 Apr;14(3):291–301. [PubMed: 18439051]
273.
Balkrishnan R, Bhosle MJ, Camacho FT, et al. Predictors of medication adherence and associated health care costs in an older population with overactive bladder syndrome: a longitudinal cohort study. J Urol. 2006 Mar;175(3 Pt 1):1067–71. discussion 1071–2. [PubMed: 16469620]
274.
Lawrence M, Guay DR, Benson SR, et al. Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy. 2000 Apr;20(4):470–5. [PubMed: 10772377]
275.
Yu YF, Nichol MB, Yu AP, et al. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program. Value Health. 2005 Jul-Aug;8(4):495–505. [PubMed: 16091027]
Cover of Treatment of Overactive Bladder in Women
Treatment of Overactive Bladder in Women.
Evidence Reports/Technology Assessments, No. 187.
Hartmann KE, McPheeters ML, Biller DH, et al.

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...